Clinical trial
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in…
NCT03927274 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT03927274 |
|---|---|
| Title | Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma |
| Official title | A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Status | Terminated |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Glioma of Brain |
| Intervention type | Drug |
| Interventions | Topotecan |
| Enrollment | 3 |
| Start date | Jun 20, 2019 |
| Primary completion | May 24, 2023 |
| Completion | May 24, 2023 |
| First posted | Apr 25, 2019 |
| Last update posted | May 25, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: